Spotlight on ixazomib: potential in the treatment of multiple myeloma. Muz B et al. Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. eCollection 2016. Immune Checkpoint Blockade in Lymphoid Malignancies. Thanarajasingam G et al, FEBS J. 2016 Jan 25. doi: 10.1111/febs.13668. [Epub ahead of print]. Elotuzumab: First Global Approval. Markham A. Drugs. 2016 Jan 26. [Epub ahead of print]. TAK-228 (formerly MLN0128), an…
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Johnson DC et al. Nat Commun. 2016 Jan 8;7:10290. doi: 10.1038/ncomms10290. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway. Zhang Z et al. Oncotarget. 2016 Jan 22. doi: 10.18632/oncotarget.6974. [Epub ahead of print]. Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Bartee…
Multiple Myeloma: Diagnosis and Treatment. Rajkumar SV et al. Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007. Management of relapsed multiple myeloma: Recommendations of the international myeloma working group. Laubach J et al. Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.356. [Epub ahead of print]. First hematopoietic cell transplantation in Uzbekistan: Progress through education and cooperation. Karimov K et al. Transfus Apher Sci. 2016 Jan 12. pii: S1473-0502(16)00016-1. doi: 10.1016/j.transci.2016.01.014.…
Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis. Cheng X et al. Eur Spine J. 2016 Jan 27. [Epub ahead of print]. Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates:From Basic Science to Medicine. Barghash RF et…
Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma. Raghupathy R et al. Br J Haematol. 2016 Jan 26. doi: 10.1111/bjh.13942. [Epub ahead of print]. Adventitious sporulation in Fusarium: The yeast that were not. Lockwood MB et al. IDCases. 2015 Dec 17;3:5-7. doi: 10.1016/j.idcr.2015.10.004. eCollection 2016. Bone Disease in Myeloma: The…
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Magarotto V et al. Blood. 2016 Jan 4. pii: blood-2015-08-662627. [Epub ahead of print]. Lenalidomide plus melphalan and prednisone, followed by lenalidomide maintenance versus thalidomide plus melphalan and prednisone, followed by thalidomide maintenance; results of the randomised phase 3 HOVON 87/NMSG18 trial.…
Percutaneous vertebroplasty for patients with metastatic compression fractures of the thoracolumbar spine: clinical and radiological factors affecting functional outcomes. Bae JW et al. Spine J. 2015 Dec 2. pii: S1529-9430(15)01694-0. doi: 10.1016/j.spinee.2015.11.033. [Epub ahead of print]. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Multiple Myeloma: Results of the Z-MARK Study.…
Imaging features of haematological malignancies of kidneys. Sandrasegaran K et al. Clin Radiol. 2015 Dec 11. pii: S0009-9260(15)00444-4. doi: 10.1016/j.crad.2015.11.007. [Epub ahead of print]. Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry? Pieri M et al. Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13878. [Epub ahead of print]. ANNALS EXPRESS: Low IgA levels…
Clinical features and prognostic factors in solitary plasmacytoma. Finsinger P et al. Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13870. [Epub ahead of print]. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Paiva B et al. Blood. 2015 Dec 14. pii: blood-2015-10-662320. [Epub ahead of print]. Isolated Tricuspid Regurgitation: Initial Manifestation of Cardiac Amyloidosis.…
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Richardson PG et al. Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Afifi S et al. Pharmacotherapy. 2015 Dec;35(12):1173-88. doi:…